# BioSystems autonomous continuation checkpoint

**Created:** 22 September 2026
**Status:** COMPLETE / SUBMISSION READY
**Branch:** `gri-biosystems-revision-20260922`
**Program authority:** SymC General Operations Manual v0.8.4
**Purpose:** allow future ChatGPT runs to resume BioSystems revision work after polling/session/tool interruptions without user intervention.

## Non-negotiable resume rule

Every continuation run must:

1. read this checkpoint first;
2. verify current branch/head and relevant workflow state;
3. continue from the first incomplete item in **Current execution queue**;
4. perform all safe/mechanical work that does not change a frozen scientific decision;
5. never retune a frozen endpoint, cohort, representation, threshold, seed, null, or comparator in response to a result;
6. update this checkpoint before ending the run;
7. preserve all failures, indeterminate results, and representation dependence;
8. keep working manuscripts private in the Project Library;
9. stop only at a genuine new scientific decision, an external-access boundary that cannot be solved mechanically, or final submission readiness.

A workflow timeout, polling timeout, chat interruption, or tool interruption is **not** a scientific stop. Resume from the latest checkpoint and workflow/artifact state.

## Frozen scientific state

### Tumor-normal reviewer control
**CLOSED.**

Internal biological closeout is frozen in:
- `GRI_v2/reviewer/BIOSYSTEMS_TUMOR_NORMAL_BIOLOGICAL_CLOSEOUT_20260922.md`
- `GRI_v2/reviewer/BIOSYSTEMS_TN_C1_BIOLOGICAL_RESULT_AUDIT_20260922.md`
- `GRI_v2/reviewer/BIOSYSTEMS_TUMOR_NORMAL_PROTOCOL_LINEAGE_AUDIT_20260922.md`

Key result:
- TN-A1 RNA: tumor lower in 12/12 cancers for all three primary RNA architecture coordinates; BH q=0.000488 each.
- TN-P20 paired sensitivity: same direction 13/13, 13/13, 12/13; q<=0.00342.
- TN-C1: H1 lower in tumor 5/5 with all cancer construction intervals below zero; H2/H3a heterogeneous; H3b small upward tendency without q<0.05 resolution.

Supported interpretation:
**tumor-associated reorganization of pre-existing tissue architecture, dominated by loss of within-layer/modular coherence rather than wholesale disappearance of organization.**

Do not upgrade this static result to recovery failure, causality, biological chi, or a universal boundary.

### Biological chi / recovery program
Do **not** reopen the closed historical `Chi_bio` admission cycle inside this BioSystems revision.

Historical disposition remains:
- scalar Chi_bio NOT_ADMITTED for the tested lineage;
- current SCC25 R1/A3 scalar admission refused as representation-dependent;
- normalized empirical G1 blocked by restoration identifiability;
- broader recovery hypothesis remains scientifically compatible with current tumor-normal findings but requires a new lineage and causally/dynamically informative recovery evidence.

BioSystems submission work has priority. Chi_bio/recovery is the next dedicated investigation after this revision is locked. The distance assessment is formalized in `GRI_v2/docs/GRI_CHI_BIO_DISTANCE_TO_ADMISSION_20260922.md` (commit `979cf5e...`): recovery is a focused new dynamical investigation, while scalar chi admission still requires a new lineage with restoration identifiability, scalar derivation, representation robustness, native-baseline incremental value, prospective boundary testing if applicable, and independent transport. Do not delay the current revision for this.

### External validation reviewer gate
**CLOSED WITH LIMIT.**

Frozen source:
- RNA: GSE237995
- 450K methylation: GSE262522
- EPIC methylation sensitivity: GSE262524

Frozen protocol:
- `GRI_v2/reviewer/BIOSYSTEMS_EXTERNAL_PROSTATE_P1_FREEZE_20260922.md`
- `GRI_v2/config/biosystems_external_prostate_p1_v1_0.json`

Primary:
- 30 paired participants from the 32 complete 450K tumor/adjacent pairs;
- P1-H1 `delta_s`;
- P1-H2 `delta_cka`;
- P1-H3a `delta_a_patient`;
- B=999 endpoint-appropriate nulls/permutations;
- BH over H1/H2/H3a;
- outcome classes FULL / PARTIAL / NO TRANSPORT / REPRESENTATION_DEPENDENT / INDETERMINATE.

Mandatory sensitivities:
- full n=32 450K pair set;
- all 26 complete EPIC pairs;
- neither sensitivity may rescue the frozen primary.

Secondary:
- external paired tumor-normal RNA corroboration of `C_in,pair`, `C_in,PC1`, and `C_out`;
- frozen directional hypothesis is tumor < adjacent.

No biological chi, recovery, causal methylation->RNA, treatment-response, or clinical claim is part of this P1 task.

## External result closure

Frozen independent prostate P1 completed successfully:
- workflow run: `35801966289`;
- artifact: `GRI_BIOSYSTEMS_EXTERNAL_PROSTATE_P1_V01`;
- artifact ID: `10726636434`;
- artifact digest: `sha256:1d7bbef7a4f8ea0cb254c139879e8ec53b9498f8d95c9c97fa28f21367075cde`;
- primary 450K n=30: H1 PASS (effect +0.303090, BH q=0.003), H2 unresolved, H3a no transport;
- full n=32 450K sensitivity: concordant;
- EPIC n=26: H1 PASS (effect +0.358394, q=0.003), H2/H3a sign-reverse and remain unresolved;
- final preregistered class: `P1_REPRESENTATION_DEPENDENT`;
- secondary external paired RNA tumor-normal replication: not confirmed.

No rescue was performed.

## Private manuscript state

Private Library folder:
`/Atlas - GRI update v1/Private Working Manuscripts/Oncology`

Final private main:
- `GRI_BioSystems_working_v10_2026-09-23.tex`;
- `GRI_BioSystems_working_v10_2026-09-23.pdf`.

Final private supplement:
- `GRI_BioSystems_supplement_working_v8_2026-09-23.tex`;
- `GRI_BioSystems_supplement_working_v8_2026-09-23.pdf`.

Final reviewer package:
- `BioSystems_Response_to_Reviewers_v2_2026-09-23.md/.pdf`;
- `BioSystems_Cover_Letter_v2_2026-09-23.md/.pdf`;
- five release figures;
- `BioSystems_Resubmission_Package_20260923.zip`.

Private bundle SHA-256:
`125a5432355835cd5fdc4f835cb3ad3cc3665c27e4ae30f7f3f332cae620e431`.

Do not publish the private manuscript/submission bundle to the public Biomedical repository.

## Current execution queue

### Q1 - external P1 implementation and preflight
**COMPLETE.**

Build the outcome-bearing external prostate runner by transporting the already frozen C1 constructions, not inventing new statistics.

Required before result opening:
- bind exact source hashes from source preflight;
- bind exact 30 primary participants;
- bind the existing C1 450K-compatible probe/gene support and Hallmark source;
- bind deterministic Ensembl->gene-symbol mapping rule;
- implement H1/H2/H3a with B=999 frozen nulls;
- implement full n=32 and EPIC sensitivities;
- implement secondary paired RNA tumor-normal test;
- write tests/known-shape fixtures;
- run an outcome-blind mechanical preflight if needed.

Scientific rules may not change.

### Q2 - execute external P1
**COMPLETE.** Frozen run `35801966289` succeeded; artifact `10726636434`, digest `sha256:1d7bbef7a4f8ea0cb254c139879e8ec53b9498f8d95c9c97fa28f21367075cde`. Primary 450K n=30 = `P1_PARTIAL_TRANSPORT`; full n=32 concordant; EPIC reproduces H1 but reverses H2/H3a signs; final preregistered disposition = `P1_REPRESENTATION_DEPENDENT`. No rescue performed.

Historical instruction retained below for audit:
After Q1 mechanical/identity gates pass, execute the frozen external result.

On completion:
- audit source/config/code/artifact identities;
- report every endpoint, including failures;
- classify FULL/PARTIAL/NO TRANSPORT/REPRESENTATION_DEPENDENT/INDETERMINATE strictly under the frozen contract;
- do not rescue a failed primary with n=32 or EPIC.

### Q3 - manuscript integration
**COMPLETE.** Final private main is v10; supplement is v8. External P1, tumor-normal, declarations, figures, captions, citations and claim ceilings are synchronized.

Integrate the external result into the private working manuscript:
- abstract;
- Methods;
- Results;
- Discussion;
- Limitations;
- conclusion;
- relevant tables/figure plan;
- exact external-validation claim ceiling.

If P1 fails or partially transports, narrow the manuscript exactly as required rather than redesigning P1.

### Q4 - reviewer package
**COMPLETE.** Reviewer matrix, claim map, resubmission closeout, final reviewer index, response letter v2 and cover letter v2 are synchronized to the completed P1 and final release.

Update:
- `BIOSYSTEMS_REVIEWER_RESPONSE_MATRIX_20260922.md`
- `BIOSYSTEMS_RESUBMISSION_CLOSEOUT_20260922.md`
- point-by-point reviewer response;
- claim/evidence map;
- non-claim ledger;
- source/result hash manifest;
- figure/table regeneration/provenance map;
- editor-facing author-initiated correction delta.

### Q5 - final submission mechanics
**COMPLETE.** All scientific evidence gates and release mechanics are closed. Five release figures were regenerated from audited aggregates without reopening the heavy C1 science run. Main and supplement PDFs passed render/visual QA; final main v10 differs from the inspected v9 only in the updated Elsevier AI-declaration heading on page 17.

Complete:
- final figures/tables;
- citation/source verification;
- axis/unit audit;
- current BioSystems policy boilerplate and disclosures;
- data/code availability;
- competing interests/funding/contributions;
- immutable submission tag/release;
- clean-room/reviewer-package audit;
- PDF visual inspection;
- final release checklist.

## Stop conditions

Do **not** stop for:
- polling delays;
- queued/in-progress GitHub jobs;
- a failed mechanical workflow if a scientific rule-preserving repair is available;
- packaging failures;
- stale workflow runs;
- manuscript synchronization chores.

Stop and surface the issue only for:
- a choice that changes the frozen scientific question;
- a source/access defect that makes the frozen P1 scientifically non-evaluable and cannot be repaired without changing the contract;
- a contradiction that invalidates an upstream frozen result;
- a genuine new user decision required by the GOM;
- final submission readiness.

## Final completion condition

All completion conditions are satisfied:

1. external P1 is dispositioned under the frozen contract;
2. manuscript and reviewer response are synchronized;
3. reviewer concerns are closed, bounded, or explicitly not claimed;
4. final release/reproducibility package passes;
5. submission-ready files are available privately to the user.

Public release records:
- `GRI_v2/reviewer/BIOSYSTEMS_FINAL_REVIEWER_INDEX_20260923.md`;
- `GRI_v2/reviewer/BIOSYSTEMS_FINAL_RESUBMISSION_RELEASE_AUDIT_20260923.md`.

**STATUS: COMPLETE / SUBMISSION READY**

Do not start a new scientific branch automatically from this checkpoint.